TY  - JOUR
AU  - Argüelles Arias, Federico
AU  - Hinojosa Del Val, Joaquín
AU  - Vera Mendoza, Isabel
PY  - 2018
DO  - 10.17235/reed.2018.5456/2018
SN  - 1130-0108
UR  - http://hdl.handle.net/10668/12230
T2  - Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva
AB  - In 2013, the European Medicines Agency (EMA) approved the biosimilar infliximab (CT-P13) for the full range of indications of the originator product, based on data from two trials conducted in rheumatoid arthritis and ankylosing spondylitis. The same...
LA  - en
KW  - Anti-Inflammatory Agents
KW  - Biosimilar Pharmaceuticals
KW  - Humans
KW  - Inflammatory Bowel Diseases
KW  - Infliximab
KW  - Practice Guidelines as Topic
TI  - Update of the SEPD position statement on the use of biosimilars for inflammatory bowel disease.
TY  - research article
VL  - 110
ER  -